Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable ...
ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once ...
Treatment of acute myeloid leukemia (AML) has remained a challenge, partly because of an insufficient understanding of the molecular mechanisms that promote and maintain the leukemic state of AML ...
NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...
Revuforj, a menin inhibitor, is under priority review for relapsed or refractory mutant NPM1 AML, with a target action date of October 25, 2025. The AUGMENT-101 trial demonstrated Revuforj's efficacy, ...
A Prescription Drug User Fee Act target date of November 30, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...
Revuforj is approved for relapsed/refractory AML with NPM1 mutation in patients aged one year and older, based on AUGMENT-101 trial results. The drug inhibits menin's interaction with KMT2A, slowing ...
Credit: Kura Oncology and Kyowa Kirin. The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML ...
The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Ziftomenib's efficacy was evaluated among 112 adults in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results